These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 25674240)

  • 21. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rate.
    Sarode VR; Xiang QD; Christie A; Collins R; Rao R; Leitch AM; Euhus D; Haley B
    Arch Pathol Lab Med; 2015 Jul; 139(7):922-8. PubMed ID: 26125432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia.
    Satti MB
    Histopathology; 2011 Sep; 59(3):537-42. PubMed ID: 21668473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
    Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
    Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
    Shukla S; Singh BK; Pathania OP; Jain M
    Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
    Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
    J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A; Sobol M; Patera J
    Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of EDTA decalcification on estrogen receptor and progesterone receptor immunohistochemistry and HER2/neu fluorescence in situ hybridization in breast carcinoma.
    Washburn E; Tang X; Caruso C; Walls M; Han B
    Hum Pathol; 2021 Nov; 117():108-114. PubMed ID: 34461131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
    Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
    Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics].
    Li HH; Ma F; Zeng X; Wang JY; Yuan P; Fan Y; Xu BH
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(2):76-80. PubMed ID: 21418986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concordance of HER2 Immunohistochemistry and Fluorescence
    Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
    Anticancer Res; 2017 Jun; 37(6):3323-3329. PubMed ID: 28551685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
    Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
    Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
    Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
    Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
    Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.
    Agersborg S; Mixon C; Nguyen T; Aithal S; Sudarsanam S; Blocker F; Weiss L; Gasparini R; Jiang S; Chen W; Hess G; Albitar M
    Breast Cancer Res Treat; 2018 Jul; 170(2):321-328. PubMed ID: 29564742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.
    Annaratone L; Simonetti M; Wernersson E; Marchiò C; Garnerone S; Scalzo MS; Bienko M; Chiarle R; Sapino A; Crosetto N
    Oncotarget; 2017 Mar; 8(12):18680-18698. PubMed ID: 28423635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples.
    Pu T; Guo P; Qiu Y; Chen S; Yang L; Sun L; Ye F; Bu H
    Int J Clin Exp Pathol; 2015; 8(9):10565-74. PubMed ID: 26617766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.